MedTrace Logo

Clinical Outcomes of Patients with a Light Adjustable Lens (LAL) in At Least One Eye

NCT06016231 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-10-21

No results posted yet for this study

Summary

To collect data on bilateral pseudophakic patients implanted with the RxSight Light Adjustable Lens (LAL) in at least one eye

Conditions

  • IOL

Interventions

DEVICE

Light Adjustable Lens

The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.

Sponsors & Collaborators

  • Bucci Laser Vision Institute

    lead OTHER

Principal Investigators

  • Frank A Bucci, MD · Bucci Laser Vision Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06016231 on ClinicalTrials.gov